Oracle Slides to $131 as Long Holders Keep Selling

ORCL closed Tuesday at $131.14, up 1.2% on the day but still down 8.4% on the week, extending a slide that has now erased 11% over the past month and left the stock roughly 19% below its September peak as the fiscal Q2 report on November 18 draws closer.

The most telling aspect of the decline remains where the pressure is coming from. Short interest dipped 3.3% on the week to 48 million shares, equal to just 1.7% of the free float, and the borrow market offers no resistance whatsoever: availability is at its ceiling, with shares to lend vastly outnumbering those already borrowed. Cost to borrow has actually fallen 16% over the week to 0.34%, a trivially low rate. This is not a short-selling story. The selling has been coming from long holders unwinding positions, and the options market is only now beginning to reflect that unease. The put/call ratio has edged up to 0.91, nearly 1.7 standard deviations above its 20-day average of 0.86, the most defensive options positioning since late September. That is a meaningful shift from the relaxed 0.84 reading noted a week ago, though still well below the 52-week high of 1.06, so protection-buying is rising rather than acute.

The Street has not abandoned the bull case. Most recent analyst actions clustered around the September 11 earnings release, when the dominant response was to hold Buy ratings while trimming targets. UBS and Barclays both moved targets modestly higher, to $250 and $252 respectively, while Stifel and RBC cut theirs, to $200 and $165. The consensus price target sits near $237, implying roughly 80% upside from current levels, a gap that reflects genuine disagreement about Oracle's trajectory rather than bullish complacency. The bull argument centres on cloud revenue running at 41% year-on-year growth and AI infrastructure bookings surging 243%, with remaining performance obligations up 325% and management guiding fiscal 2027 revenue toward $90 billion. Bears point to competitive pressure in Oracle's legacy database business, execution risk on AI monetisation, and foreign exchange exposure. Valuation multiples have compressed alongside the share price: the price-to-earnings ratio has fallen nearly 2 points over the past month to 12.6x, and the EPS momentum score ranks in the 72nd percentile on a 30-day basis, suggesting estimate revisions are still running in the right direction even as the share price falls.

One insider purchase stands out against an otherwise mixed register. Director Stephen Rusckowski bought 25,000 shares in the open market on September 29 at $139.35, a $3.5 million commitment made without the cover of a pre-arranged trading plan. That is a meaningful discretionary purchase. Against it, CEO Michael Sicilia sold 22,562 shares on September 22 at $151.59, though that sale was executed under a 10b5-1 plan, a pre-scheduled transaction that carries less informational weight. The 90-day net insider position is a small net sale of roughly 11,000 shares in value terms, so the Rusckowski purchase is notable precisely because it runs against the wider insider current, at a price the stock has since broken below.

The previous report, published October 19, described the sequence of lower highs as accelerating and noted the stock had printed a fresh cycle low at $128.23. Tuesday's close at $131.14 is a modest recovery from that point, and the October 14 note documented a similar brief bounce to $143.20 that subsequently failed. Whether this week's 1.2% gain holds a different character than those earlier attempts is the question the November 18 print will eventually answer, with the stock now carrying a sequence of failed recoveries as the backdrop and the Street's price targets more than $100 above where shares are trading.